A Single Ascending Dose Trial of CVL-936 in Healthy Subjects

Summary

The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CVL-936 following single ascending oral doses in healthy subjects.

Timeline

Start

2019-12-16

Primary completion

2020-03-06

Completion

2020-05-21

Outcome

Outcome not reported

Stopped: “Sufficient data has been obtained to meet current objectives”

Drugs

Indications